Signifor lar kit, Signifor(pasireotide)
Signifor (pasireotide) is a protein pharmaceutical. Pasireotide was first approved as Signifor on 2012-04-24. It is used to treat cushing syndrome in the USA. It has been approved in Europe to treat acromegaly and pituitary acth hypersecretion. The pharmaceutical is active against somatostatin receptor type 3, somatostatin receptor type 1, somatostatin receptor type 2, and somatostatin receptor type 5.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Signifor
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| signifor | New Drug Application | 2025-04-10 |
| signifor lar | New Drug Application | 2024-07-16 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cushing syndrome | EFO_0003099 | D003480 | E24 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PASIREOTIDE PAMOATE, SIGNIFOR LAR KIT, RECORDATI RARE | |||
| 2025-06-29 | ODE-268 | ||
HCPCS
Code | Description |
|---|---|
| J2502 | Injection, pasireotide long acting, 1 mg |
Clinical
Clinical Trials
85 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | — | — | — | 1 | 1 | 2 |
| Acth-secreting pituitary adenoma | D049913 | — | — | — | — | — | 1 | 1 | 2 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 1 | — | 1 | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | — | 1 | — | 1 |
| Melanoma | D008545 | — | — | — | — | — | 1 | — | 1 |
| Pituitary neoplasms | D010911 | — | — | — | — | — | 1 | — | 1 |
| Pituitary diseases | D010900 | — | E23.7 | — | — | — | 1 | — | 1 |
| Dumping syndrome | D004377 | EFO_1001307 | K91.1 | — | — | — | 1 | — | 1 |
| Acromegaly | D000172 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Pasireotide |
| INN | pasireotide |
| Description | Pasireotide is a six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease. It has a role as an antineoplastic agent. It is a homodetic cyclic peptide and a peptide hormone. It is a conjugate base of a pasireotide(2+). |
| Classification | Protein |
| Drug class | peptides: inhibition of growth hormone release |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O |
Identifiers
| PDB | — |
| CAS-ID | 396091-73-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3039583 |
| ChEBI ID | — |
| PubChem CID | 9941444 |
| DrugBank | DB06663 |
| UNII ID | 98H1T17066 (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,625 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,559 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use